Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-T187 in Advanced Solid Tumors
NCT06598800Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Oct 2024
- Primary completion
- Sep 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Trispecific Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of BG-T187 in solid tumor (5 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events, Maximum Administered Dose or Maximum Tolerated Dose of BG-T187 and 3 more. Started Oct 2024; status: recruiting.
02
Drugs
BG-T187
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06598800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598800.